aflibercept

has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders

Also Known As:

AVE 0005; AVE 005; AVE-0005; AVE-005; AVE0005; AVE005; VEGF Trap - regeneron; VEGF Trap-Eye; VEGF-Trap; ZIV-aflibercept; Zaltrap; eylea

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        aflibercept: 1993
      - Peptide Receptors: 1159
        Growth Factor Receptors: 2663
        Vascular Endothelial Growth Factor Receptors: 3385
        aflibercept: 1993
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - aflibercept: 1993
  - Intracellular Signaling Peptides and Proteins: 32
    - Protein-Tyrosine Kinases: 7697
      - Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        aflibercept: 1993
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Phosphotransferases: 42769
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9677
        Protein-Tyrosine Kinases: 7697
        Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        aflibercept: 1993

Vinicius Ferreira Kniggendorf Selected Research

Vinicius Ferreira Kniggendorf Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure